Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Remetinostat in Cutaneous SCC
NCT03875859Phase 2Terminated
- Start
- Dec 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of remetinostat in cutaneous squamous cell carcinoma (cSCC). Primary endpoint: Overall Response Rate at 10 weeks. Started Dec 2019; status: terminated.
02
Drugs
remetinostat
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT03875859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875859.